Hailong Liu

Hailong Liu

Auto-generated profile, based on publicly available information

Hailong Liu

Center for Clinical Research and Translational Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in International Journal of Surgery
Verified
Journal Article
Closed access
HLHailong Liu
Hailong Liu
XTXuan Tang
Xuan Tang
YCYi Chang
Yi Chang
ALAjian Li
Ajian Li
ZLZhen Li
Zhen Li
HJHuihong Jiang
Huihong Jiang
Video-assisted anal fistula treatment (VAAFT) is a new minimally invasive technique for treating complex anal fistula (CAF). This study aimed to compare the efficacy and safety of VAAFT with fistulotomy plus seton (FPS) for treatment of CAF. We included 148 patients with CAF receiving surgical treatment at our hospital between January 2017 and December 2018. Propensity score matching (PSM) analysis was conducted with patients' baseline characteristics, and surgical outcomes were compared between the matched groups. Logistic analysis was performed to identify the risk factors for fistula recurrence after VAAFT. Among the study population, 68 and 80 patients underwent VAAFT and FPS, respectively. After PSM, 64 matched pairs of patients were created with no significant differences in baseline characteristics. Compared with FPS, VAAFT had greater efficiency of locating internal openings (90.6% vs. 100%), less intraoperative blood loss (26 ± 15 vs. 12 ± 5 mL), lower incidence of postoperative bleeding (10.9% vs. 1.5%), shorter postoperative hospital stay (6.8 ± 5.1 vs. 5.0 ± 3.3 days), reduced postoperative pain, and decreased wound secretion (all P < 0.05). VAAFT showed a significantly lower Wexner incontinence score than FPS (0.9 ± 1.7 vs. 1.9 ± 2.6, P = 0.003) at 3 months postoperatively, but no significant difference in the healing rate was observed either at 3-month or 1-year (P = 1.000) follow-up. A total of 12 patients (17.6%) developed fistula recurrence after VAAFT, and logistic analysis revealed that multiple fistula tracts, prolonged operating time and severe postoperative wound secretion were independent risk factors (odds risk = 2.18, 3.25 and 3.04, respectively, all adjusted P < 0.05). Compared with FPS, VAAFT offers some advantages for treatment of CAF, including minimal damage, less pain, rapid recovery, fewer complications and better sphincter preservation.

19 December 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
XCXia Chen
Xia Chen
AWAi-Li Wang
Ai-Li Wang
YLYuan-Yuan Liu
Yuan-Yuan Liu
CZChen-Xi Zhao
Chen-Xi Zhao
XZXue Zhou
Xue Zhou
MLMo-Bin Lin
Mo-Bin Lin
Colorectal cancer (CRC) is a leading cause of cancer-related death around the world whose recurrence and metastasis rate is high. Due to the underlying unclear pathogenesis, it is hard so far to predict the tumorigenesis and prevent its recurrence. YAP/TAZ has been reported to be activated and functioned as a potential oncogene in multiple cancer types and proved to be essential for the carcinogenesis of most solid tumors. In the present study, we found that YAP/TAZ was markedly upregulated in CRC tissues comparing with the adjacent noncancerous tissues due to the downregulation of LATS2, the main upstream regulator. We further identified miR-429 as a direct regulator of LATS2-YAP/TAZ activation, suggesting that the miR-429-LATS2-YAP/TAZ might be novel effective diagnostic axis and therapeutic targets for CRC.

24 January 2025 in Cancer Research
Verified
Journal Article
Closed access
RCRan Chen
Ran Chen
CMCuihong Ma
Cuihong Ma
HQHaoran Qian
Haoran Qian
XXXinyu Xie
Xinyu Xie
YZYuxue Zhang
Yuxue Zhang
DGDaming Gao
Daming Gao
Intrahepatic cholangiocarcinoma (iCCA) is a lethal malignancy affecting the liver and biliary system. Enhanced understanding of the pathogenic mechanisms underlying iCCA tumorigenesis and the discovery of appropriate therapeutic targets are imperative to improve patient outcomes. In this study, we investigated the functions and regulations of solute carrier family 16 member 3 (SLC16A3), which has been reported to be a biomarker of poor prognosis in iCCA. High SLC16A3 expression was enriched in KRAS viral oncogene homolog–mutated iCCA tumors, and mutant KRAS elevated SLC16A3 expression via the PI3K–AKT–mTORC1–HIF1α pathway. SLC16A3 not only enhanced glycolysis but also induced epigenetic reprogramming to regulate iCCA progression. Phosphorylation of SLC16A3 at S436 was vital for its oncogenic function and was linked to iCCA progression. Casein kinase 2 (CK2) directly phosphorylated SLC16A3 at S436, and CK2 inhibition with CX-4945 (silmitasertib) reduced the growth of KRAS-mutated iCCA tumor xenografts and patient-derived organoids. Together, this study provides valuable insights into the diverse functions of SLC16A3 in iCCA and comprehensively elucidates the upstream regulatory mechanisms, providing potential therapeutic strategies for patients with iCCA with KRAS mutations. Significance: Characterization of the oncogenic function and regulators of SLC16A3 in intrahepatic cholangiocarcinogenesis revealed the potential of CK2 inhibitors as a promising treatment for KRAS-mutated tumors.

3 April 2025
Verified
Other
Open access
PDF file
RCRan Chen
Ran Chen
CMCuihong Ma
Cuihong Ma
HQHaoran Qian
Haoran Qian
XXXinyu Xie
Xinyu Xie
YZYuxue Zhang
Yuxue Zhang
DGDaming Gao
Daming Gao
Supplementary Table S2 shows the GO enrichment for 43 genes in Supplementary Table S1.

3 April 2025
Verified
Other
Open access
PDF file
RCRan Chen
Ran Chen
CMCuihong Ma
Cuihong Ma
HQHaoran Qian
Haoran Qian
XXXinyu Xie
Xinyu Xie
YZYuxue Zhang
Yuxue Zhang
DGDaming Gao
Daming Gao
Supplementary Table S1 shows the 43 ChIP-seq and RNA-seq overlapped genes with good prognosis.

17 June 2026
Verified
Other
Open access
RCRan Chen
Ran Chen
CMCuihong Ma
Cuihong Ma
HQHaoran Qian
Haoran Qian
XXXinyu Xie
Xinyu Xie
YZYuxue Zhang
Yuxue Zhang
DGDaming Gao
Daming Gao
Supplementary Table S3 shows the genes used to calculate the HIF1A signature score.